Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compliance with GRAZAX in adults with seasonal grass pollen induced rhinoconjunctivitis
2005-004724-39Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2005
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of phleum pratense allergen extract in allergic rhinoconjunctivitis (ARC), grass pollen allergy and asthma (2 arms), sponsored by ALK-Abelló. Primary endpoint: Treatment compliance (excellent vs less excellent). Started Dec 2005; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)grass pollen allergyasthma
Beyond the preview
Go deeper on 2005-004724-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004724-39.